BRENNEN

Industries / Health / Healthcare / Weight-loss clinics

Online clinics

Online clinics sell weight-loss care through an app or website: a questionnaire or video visit, a prescriber's decision, drugs shipped to the door and coaching by message, and drug makers now sell to patients the same way.

7

Milestones achieved, from 2022 to 2026.

2

To watch for: announced, not yet confirmed outside.

2

Open deliverables. Nobody has shipped them.

The road

AchievedWatch forOpen

Achieved

  1. 2022

    Hard-to-cancel trials cost Noom

    Noom, a New York company whose app coaches weight loss through lessons and food logging, agreed in February 2022 to a $62 million settlement of a lawsuit in Manhattan federal court: $56 million in cash and $6 million in subscription credits. Customers said "risk-free" trials rolled into automatic renewals that were hard to cancel, with up to eight months of nonrefundable payments totaling as much as $199. Noom denied wrongdoing, and the company and the customers' lawyers valued its changes to its business practices at $31.2 million to $120 million.

    LessonAn online program's sign-up and cancel steps draw as much legal attention as its health claims.

    euronews.com

    Credit

    the Noom customers who sued

  2. 2023

    A diet company buys prescribers

    WeightWatchers (WW International), which began as a group diet program, agreed on 4 March 2023 to buy Weekend Health, trading as Sequence, a subscription telehealth service whose clinicians prescribe weight-loss drugs, for $132.0 million, including at least $26.0 million of Sequence's own cash. The deal closed on 10 April 2023, and WW later made Sequence's service its clinical tier, Med+.

    sec.govsec.gov

    Credit

    WW International; Sequence

  3. 2024

    Drug makers sell direct

    In the summer of 2024 Eli Lilly began selling vials of its weight-loss drug Zepbound online through LillyDirect, its direct-to-consumer site, to patients paying cash with a prescription from their own doctor or from an online prescriber partnered with Lilly. On 5 March 2025 Novo Nordisk followed with NovoCare Pharmacy, which sells Wegovy for $499 a month to patients without insurance and to those whose insurance does not cover obesity drugs. Neither offer can be paid for by health insurance, NPR reported.

    kunc.orgdrugtopics.com

    Credit

    Eli Lilly; Novo Nordisk

  4. 2025

    A drug maker drops Hims

    In late April 2025, after the FDA declared the Wegovy shortage over, Novo Nordisk began supplying Wegovy through NovoCare Pharmacy to the telehealth companies Hims & Hers, LifeMD and Ro. On 23 June 2025 it ended the arrangement with Hims & Hers, saying the company kept selling compounded semaglutide "under the false guise of 'personalization'" and marketed it deceptively. Hims & Hers' chief executive, Andrew Dudum, said Novo had pressured the company to steer patients to Wegovy, and Hims & Hers shares fell about 30% that day.

    LessonA platform that sells a brand-name drug alongside cheaper copies of it can lose its supply of the brand.

    novonordisk-us.comfiercehealthcare.com

    Credit

    Novo Nordisk; Hims & Hers

  5. 2025

    WeightWatchers goes bankrupt

    On 6 May 2025 WW International and seven subsidiaries filed for Chapter 11 bankruptcy protection in Delaware with a reorganization plan already agreed with lenders, and the plan took effect on 24 June 2025. In its next annual report WW said revenue from its behavioral (diet program) subscriptions fell because fewer new subscribers joined, while revenue from clinical subscriptions rose with demand for weight-loss drugs. At the end of 2025 it had about 2.6 million behavioral subscribers and about 130,200 clinical subscribers.

    sec.govsec.govsec.gov

    Credit

    WW International; US Bankruptcy Court for the District of Delaware

  6. 2026

    Undercover buyers get jabs

    In January 2026 an ITV News reporter edited photos to look larger, uploaded them, and within a week three online pharmacies had approved the reporter and sent Mounjaro, a prescription weight-loss injection; the General Pharmaceutical Council (GPhC), which regulates British pharmacies, said it had acted against about 18 pharmacies whose online checks fell short. In May 2026 Which?, a UK consumer group, posed as a first-time patient with a true overweight BMI and a false claim of high blood pressure. Superdrug, MedExpress, Voy and Zava sent injections without checking the claim; Boots, Numan, Morrisons and Pharmacy2U refused without genuine GP details; Simple Online Pharmacy and MyJuniper asked for proof.

    LessonThe same rules on checks are applied very differently from one provider to the next.

    news.stv.tvwhich.co.uk

    Credit

    ITV News; Which? (Sara Spary)

  7. 2026

    A test patient, 45 prescriptions

    Between August and December 2025 a researcher posing as a patient who qualified for a GLP-1 drug sought it from 49 US websites selling semaglutide or tirzepatide, branded, compounded or both. Forty-five sites (91.8%) issued a prescription and 34 (69.4%) mailed the drug, with a median time to prescription of a day or less; 13 required a video visit and 27 asked about eating disorders. Nine sites prescribed when the patient sent only an upper-body photo where a full-body or scale photo was required, and three clinicians prescribed for the same patient on two or more sites.

    LessonThe checks a site lists are not always the checks it applies.

    ajmc.comeuropepmc.org

    Credit

    A. K. Chetty, A. S. Chen, J. S. Ross and R. Ramachandran, in JAMA, July 2026

Watch for

  1. Smaller doses, fewer side effects

    Noom's Microdose GLP-1 program, launched in August 2025 from $119 a month, prescribes compounded GLP-1 drugs at lower doses than the standard ones. Noom says preliminary data from the program show that 70% of patients report no side effects at all. An obesity specialist quoted by MedCity News, Disha Narang of Endeavor Health, questioned the use of compounded drugs whose contents and dose equivalents are unclear.

    Achieved whena randomized trial run or analyzed by researchers independent of Noom reports side effects and weight change on these doses against standard dosing.

    medcitynews.com

    Claimed by

    Noom, August 2025

  2. Prices matched to other countries

    TrumpRx.gov, a US government site launched on 5 February 2026, lists cash prices that drug makers agreed in "Most-Favored-Nation" pricing deals with the White House. It says the monthly price of injectable Wegovy falls from $1,349 to an average of $350 and as low as $199, depending on dose, and that the deals "ensure Americans pay prices aligned with the lowest in other developed nations".

    Achieved whenan independent comparison of TrumpRx cash prices with prices paid in the peer countries confirms that they match the lowest.

    whitehouse.gov

    Claimed by

    the White House, February 2026

Open

  1. 01

    Photo checks against edited images

    A public test set of full-body photos of made-up people, generated by image models, each in an unedited version and in versions edited to look heavier with common phone editors and AI image tools. Use it to score the checks an online clinic could run on an uploaded photo: open forgery detectors, which flag edited regions, and open models that estimate BMI from a photo. Report how often each edit is caught and how far each edit moves a model's BMI estimate. No photo of a real person is used.

    The brief
    Credit · unclaimed
  2. 02

    Who runs each brand

    A public, dated map of the consumer brands that sell prescription weight-loss treatment online in the UK, Ireland and Australia, linking each brand to the company that employs its prescribers, the pharmacy that dispenses, and the owner, with company numbers and register entries. Every link cites a register entry, a filing or the brand's own terms page, so that advertising rulings, inspection findings and press tests can be traced to the operator behind several brands.

    The brief
    Credit · unclaimed

Open 01 · the brief

Photo checks against edited images

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

A public test set of full-body photos of made-up people, generated by image models, each in an unedited version and in versions edited to look heavier with common phone editors and AI image tools. Use it to score the checks an online clinic could run on an uploaded photo: open forgery detectors, which flag edited regions, and open models that estimate BMI from a photo. Report how often each edit is caught and how far each edit moves a model's BMI estimate. No photo of a real person is used.

Why it is still open

ITV News found in January 2026 that some UK online pharmacies relied on uploaded photos alone, and its reporter's edited photos passed at three of them; in the US secret-shopper study, nine sites prescribed on an upper-body photo where they asked for a full-body one. Published work on estimating BMI from photos, such as the open-source Digital Scale model (2025, 7.9% mean error on its makers' own test set), measures accuracy on honest photos only. Searches of arXiv and GitHub in November 2026 found no test of edited weight-check photos.

news.stv.tvajmc.comarxiv.org

Built with what exists

open-weight image generators such as FLUX.1 schnell to make synthetic people; phone editors with reshape tools and AI image editors to make the edits; TruFor, an open image-forgery detector from the University of Naples (github.com/grip-unina/TruFor); the Digital Scale BMI model and the 6,105-image BMI dataset of Yaseen and colleagues (arXiv 2607.26104) as estimators; Python.

  1. First step

    Generate 50 synthetic full-body images, edit each with one reshape tool at two strengths, and run TruFor on all 150.

  2. Done looks like

    1,000 synthetic people, each unedited and at three edit strengths; for each detector, the share of edited photos caught when it wrongly flags no more than 5% of unedited ones; the average BMI shift each edit causes in each estimator; all images, labels and code published under an open license.

Open 02 · the brief

Who runs each brand

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

A public, dated map of the consumer brands that sell prescription weight-loss treatment online in the UK, Ireland and Australia, linking each brand to the company that employs its prescribers, the pharmacy that dispenses, and the owner, with company numbers and register entries. Every link cites a register entry, a filing or the brand's own terms page, so that advertising rulings, inspection findings and press tests can be traced to the operator behind several brands.

Why it is still open

One operator can sit behind several brands. Zava UK runs the online doctor for Asda and Superdrug as well as its own, and since July 2025 belongs to Hims & Hers, which has agreed to buy Australia's Eucalyptus; in Which?'s May 2026 test, Superdrug and Zava both sent injections on false information. Searches in November 2026 found no public map of these links.

sec.govwhich.co.uk

Built with what exists

Companies House's free public API and the public registers of the GPhC and the Care Quality Commission in the UK; the Companies Registration Office and the Pharmaceutical Society of Ireland register; ASIC company records and the AHPRA practitioner register in Australia; SEC EDGAR filings for listed owners; a browser agent such as Browser Use 1.0 (see the Note "Deleting 80% to start over") to collect each brand's terms page; a spreadsheet or Wikidata to hold the links.

  1. First step

    Map the pharmacies named in Which?'s May 2026 report and in the Advertising Standards Authority's July 2025 rulings to their operating companies through Companies House.

  2. Done looks like

    At least 80 brands in three countries mapped, every link sourced and dated, the number of brands per operator reported, and the map refreshed every six months.